Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Proprietary Hemopurifier Technology: Aethlon possesses unique, patented Hemopurifier technology designed to remove harmful exosomal particles, viruses, and toxins directly from the bloodstream, offering a novel extracorporeal approach to treating various life-threatening diseases.
Broad Therapeutic Pipeline Potential: The Hemopurifier's mechanism of action allows it to be explored across multiple therapeutic areas, including severe viral infections, oncology, and neurodegenerative diseases, providing diverse market opportunities and reducing reliance on a single indication.
Addressing Critical Unmet Medical Needs: Aethlon targets conditions for which existing treatments are inadequate or non-existent, positioning its technology as a potentially transformative solution for patients with few other options.
Risks
Clinical Trial Success Uncertainty: The development and eventual commercialization of the Hemopurifier are heavily dependent on the successful completion of ongoing and future clinical trials, with any setbacks or failures significantly impacting the company's prospects.
Regulatory Approval Challenges: Obtaining necessary regulatory approvals from bodies like the FDA for the Hemopurifier is a complex, time-consuming, and uncertain process, and a failure to secure these approvals would prevent market access.
Funding and Liquidity Concerns: Aethlon has incurred significant operating losses since inception and will require substantial additional capital to fund its operations and continue product development, with no guarantee of securing such funding on favorable terms.
Today
8:02 AM
Over a week ago
Jun 26, 8:07 AM
Jun 22, 9:19 AM
Mar 24, 8:08 AM
Mar 12, 8:03 AM
Feb 12, 4:17 PM
Jan 7, 4:17 PM
Dec 23, 3:09 PM
Dec 5, 9:16 AM
Dec 2, 8:07 AM
Nov 12, 4:20 PM
Oct 17, 7:50 PM
Sep 4, 9:21 AM
Sep 3, 8:05 AM
Aug 20, 5:21 PM
Aug 13, 4:18 PM
Jul 15, 8:05 AM
No more stories
